Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial

Human papillomavirus (HPV)‐based cervical cancer screening requires triage of HPV positive women to identify those at risk of cervical intraepithelial neoplasia grade 2 (CIN2) or worse. We conducted a blinded case–control study within the HPV FOCAL randomized cervical cancer screening trial of women...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Darrel A., Krajden, Mel, Brentnall, Adam R., Gondara, Lovedeep, Chan, Tracy, Law, Jennifer H., Smith, Laurie W., van Niekerk, Dirk J., Ogilvie, Gina S., Coldman, Andrew J., Warman, Rhian, Reuter, Caroline, Cuzick, Jack, Lorincz, Attila T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492122/
https://www.ncbi.nlm.nih.gov/pubmed/30412281
http://dx.doi.org/10.1002/ijc.31976
_version_ 1783415086153465856
author Cook, Darrel A.
Krajden, Mel
Brentnall, Adam R.
Gondara, Lovedeep
Chan, Tracy
Law, Jennifer H.
Smith, Laurie W.
van Niekerk, Dirk J.
Ogilvie, Gina S.
Coldman, Andrew J.
Warman, Rhian
Reuter, Caroline
Cuzick, Jack
Lorincz, Attila T.
author_facet Cook, Darrel A.
Krajden, Mel
Brentnall, Adam R.
Gondara, Lovedeep
Chan, Tracy
Law, Jennifer H.
Smith, Laurie W.
van Niekerk, Dirk J.
Ogilvie, Gina S.
Coldman, Andrew J.
Warman, Rhian
Reuter, Caroline
Cuzick, Jack
Lorincz, Attila T.
author_sort Cook, Darrel A.
collection PubMed
description Human papillomavirus (HPV)‐based cervical cancer screening requires triage of HPV positive women to identify those at risk of cervical intraepithelial neoplasia grade 2 (CIN2) or worse. We conducted a blinded case–control study within the HPV FOCAL randomized cervical cancer screening trial of women aged 25–65 to examine whether baseline methylation testing using the S5 classifier provided triage performance similar to an algorithm relying on cytology and HPV genotyping. Groups were randomly selected from women with known HPV/cytology results and pathology outcomes. Group 1: 104 HPV positive (HPV+), abnormal cytology (54 CIN2/3; 50 <CIN2); Group 2: 103 HPV+, normal cytology with HPV persistence at 12 mo. (53 CIN2/3; 50 <CIN2); Group 3: 50 HPV+, normal cytology with HPV clearance at 12 mo. (assumed <CIN2), total n=257. For the combined groups, S5 risk score CIN2/3 relative sensitivity, specificity and positive predictive value (PPV) were compared with other triage approaches. Methylation showed a highly significant increasing trend with disease severity. For CIN3, S5 relative sensitivity and specificity were: 93.2% (95%CI: 81.4–98.0) and 41.8% (35.2–48.8), compared to 86.4% (75.0–95.7) and 49.8% (43.1–56.6) respectively for combined abnormal cytology/HPV16/18 positivity (differences not statistically significant at 5% level); adjusted PPVs were 18.2% (16.2–20.4) and 19.3% (16.6–22.2) respectively. S5 was also positive in baseline specimens from eight cancers detected during or after trial participation. The S5 methylation score had high sensitivity and PPV for CIN3, compatible with US and European thresholds for colposcopy referral. Methylation signatures can identify most HPV positive women at increased risk of cervical cancer from their baseline screening specimens.
format Online
Article
Text
id pubmed-6492122
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-64921222019-05-06 Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial Cook, Darrel A. Krajden, Mel Brentnall, Adam R. Gondara, Lovedeep Chan, Tracy Law, Jennifer H. Smith, Laurie W. van Niekerk, Dirk J. Ogilvie, Gina S. Coldman, Andrew J. Warman, Rhian Reuter, Caroline Cuzick, Jack Lorincz, Attila T. Int J Cancer Tumor Markers and Signatures Human papillomavirus (HPV)‐based cervical cancer screening requires triage of HPV positive women to identify those at risk of cervical intraepithelial neoplasia grade 2 (CIN2) or worse. We conducted a blinded case–control study within the HPV FOCAL randomized cervical cancer screening trial of women aged 25–65 to examine whether baseline methylation testing using the S5 classifier provided triage performance similar to an algorithm relying on cytology and HPV genotyping. Groups were randomly selected from women with known HPV/cytology results and pathology outcomes. Group 1: 104 HPV positive (HPV+), abnormal cytology (54 CIN2/3; 50 <CIN2); Group 2: 103 HPV+, normal cytology with HPV persistence at 12 mo. (53 CIN2/3; 50 <CIN2); Group 3: 50 HPV+, normal cytology with HPV clearance at 12 mo. (assumed <CIN2), total n=257. For the combined groups, S5 risk score CIN2/3 relative sensitivity, specificity and positive predictive value (PPV) were compared with other triage approaches. Methylation showed a highly significant increasing trend with disease severity. For CIN3, S5 relative sensitivity and specificity were: 93.2% (95%CI: 81.4–98.0) and 41.8% (35.2–48.8), compared to 86.4% (75.0–95.7) and 49.8% (43.1–56.6) respectively for combined abnormal cytology/HPV16/18 positivity (differences not statistically significant at 5% level); adjusted PPVs were 18.2% (16.2–20.4) and 19.3% (16.6–22.2) respectively. S5 was also positive in baseline specimens from eight cancers detected during or after trial participation. The S5 methylation score had high sensitivity and PPV for CIN3, compatible with US and European thresholds for colposcopy referral. Methylation signatures can identify most HPV positive women at increased risk of cervical cancer from their baseline screening specimens. John Wiley & Sons, Inc. 2018-12-24 2019-05-15 /pmc/articles/PMC6492122/ /pubmed/30412281 http://dx.doi.org/10.1002/ijc.31976 Text en © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Tumor Markers and Signatures
Cook, Darrel A.
Krajden, Mel
Brentnall, Adam R.
Gondara, Lovedeep
Chan, Tracy
Law, Jennifer H.
Smith, Laurie W.
van Niekerk, Dirk J.
Ogilvie, Gina S.
Coldman, Andrew J.
Warman, Rhian
Reuter, Caroline
Cuzick, Jack
Lorincz, Attila T.
Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
title Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
title_full Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
title_fullStr Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
title_full_unstemmed Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
title_short Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
title_sort evaluation of a validated methylation triage signature for human papillomavirus positive women in the hpv focal cervical cancer screening trial
topic Tumor Markers and Signatures
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492122/
https://www.ncbi.nlm.nih.gov/pubmed/30412281
http://dx.doi.org/10.1002/ijc.31976
work_keys_str_mv AT cookdarrela evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT krajdenmel evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT brentnalladamr evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT gondaralovedeep evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT chantracy evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT lawjenniferh evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT smithlauriew evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT vanniekerkdirkj evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT ogilvieginas evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT coldmanandrewj evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT warmanrhian evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT reutercaroline evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT cuzickjack evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial
AT lorinczattilat evaluationofavalidatedmethylationtriagesignatureforhumanpapillomaviruspositivewomeninthehpvfocalcervicalcancerscreeningtrial